Cerus makes the INTERCEPT Blood System, which is used to reduce pathogens in donated blood components for transfusion. CERS reports earnings on Mon, Nov 2, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 20 | Freedom Broker | Initiated | Buy | |
| May 1 | BTIG | Upgrade | Buy |
Seasonality
How CERS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in CERS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CERS is in one of them and how their past CERS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CERS in an article yet. Here's the latest on the wider market.
About Cerus
Cerus is a biomedical products company based in Concord, California. Its main product is the INTERCEPT Blood System, which is designed to reduce bloodborne pathogens in donated blood components intended for transfusion. The system is used to treat platelets and plasma, and a related version produces a fibrinogen complex for treating bleeding linked to fibrinogen deficiency. Cerus sells these products through its own sales force and distributors in several countries, while its red blood cell system remains in development.
- Headquarters
- Concord, CA